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Abstract
Objective: To evaluate diagnostic accuracy of quantita-
tive fetal fibronectin (qfFN) test in predicting preterm 
birth (PTB) risk  < 34 weeks’ gestation or within 14  days 
from testing. We explored the predictive potential of the 
test in five-predefined PTB risk categories based on pre-
defined qfFN  thresholds ( < 10, 10–49, 50–199, 200–499 
and  ≥ 500 ng/mL).
Methods: Measurement of cervicovaginal qfFN with Rapid 
fFN 10Q System (Hologic) in 126 women with singleton 
pregnancy (23–33 weeks’ gestation) reporting signs and 
symptoms indicative of preterm labour (PTL).
Results: For PTB prediction risk  < 34 weeks’ gestation, 
sensitivity decreased from 100% to 41.7% and specificity 
increased from 0% to 99.1% with increasing fFN thresh-
olds. Positive predictive value (PPV) increased from 9.5% 
to 83.3% with increasing qfFN thresholds, while negative 
predictive value (NPV) was higher than 90% among the 
fFN-predefined categories. Diagnostic accuracy results 
showed an area under a receiving operator characteristic 
(ROC) curve of 84.5% (95% CI, 0.770–0.903). For deliv-
ery prediction within 14 days from the testing, sensitivity 
decreased from 100% to 42.8% and specificity increased 
from 0% to 100% with increasing fFN thresholds. Diag-
nostic accuracy determined by the ROC curve was 66.1% 
(95% CI, 0.330–0.902).
Conclusions: The QfFN thresholds of tests are a useful 
tool to distinguish pregnant women for PTB prediction 
risk  < 34 weeks’ gestation.
Keywords: Preterm birth prediction (PTB); quantitative 
fetal fibronectin (qfFN); symptomatic women.
Introduction
Preterm birth (PTB), occurring in approximately 11% of 
pregnancies, is the primary cause of perinatal death and 
neonatal morbidity and remains one of the most critical 
problem in obstetrics [1]. Although all births before 37 
weeks of gestation are defined as preterm, the highest rate 
of morbidity and mortality occurs for deliveries before 34 
weeks of gestation. Preterm labour (PTL) signs and symp-
toms usually used to identify women at risk for PTB are 
poor predictive indicators for an imminent delivery [2]. So 
PTB identification is an arduous problem for clinicians and 
it is crucial to be able to distinguish pregnant women at 
risk from those not at risk for PTB in order to improve neo-
natal morbidity and mortality through a successful phar-
macological treatment and to reduce healthcare costs.
Several diagnostic biophysical and biochemical 
methods have been suggested for predicting PTB. Among 
biochemical markers, fetal fibronectin (fFN), detectable in 
cervicovaginal fluid, is one of the most studied and uti-
lised tests in the clinical practice. fFN is an adhesive gly-
coprotein (450 kDa) that acts as a bonding agent for the 
maternal-fetal layer binding the maternal membranes to 
the fetal membranes. In pregnancy, cervicovaginal fFN 
is detectable during the first 22 weeks of gestation, is 
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undetectable between 22+0 and 34+0 weeks of gestation 
and again detectable after 34 gestational weeks until term. 
fFN has been shown to be a strong predictor for PTB in 
cervicovaginal fluid between 22 and 34 weeks’ gestation, 
[3–5], however, recently, it has been demonstrated that 
fFN is valuable also from 18 weeks of gestation [6].
The most used fFN bedside test (Rapid fFN TLIIQ; 
Hologic, Marlborough, MA, USA) is a qualitative test that 
provides a positive or negative result based on a single 
fFN threshold of 50 ng/mL, although limited data regard-
ing the selection and the accuracy of this cut-off point are 
available. It follows that the test in symptomatic women 
has a good negative predictive value (NPV)  > 90% [7–12], 
but has a low positive predictive value (PPV) from  < 20% 
to 40% [7, 13, 8, 11] for predicting delivery before 34 weeks’ 
gestation or within 14  days from testing with the conse-
quence that a high number of pregnant women with a 
positive qualitative fFN test will not deliver preterm.
Some studies showed that PTB risk increases with 
increasing cervicovaginal fFN concentration [9, 14, 15] and 
that the quantitative measurement of the fFN level could 
improve the accuracy in identifying women at risk of PTB. 
It has also been observed that introducing pre-specified 
threshold concentrations of fFN could further increase the 
potential prediction of the fFN test [14, 16–18].
The purpose of the present study was to evaluate the 
accuracy of a new bedside quantitative fFN test (qfFN 
testing; Rapid fFN 10Q System, Hologic), used between 
23+0 and 34+0 weeks of gestation, in predicting women 
at risk for PTB before 34 weeks’ gestation or within 14 days 
from testing. We explored the predictive potential of the 
test in five predefined PTB risk categories, based on pre-
defined fFN threshold concentrations; PTB risk classes 
were classified from low (fFN < 10 ng/mL) to high PTB risk 
(fFN ≥ 500 ng/mL) (Table 1).
Patients
We performed a prospective multicentre study to evaluate 
whether the quantitative measurement of cervicovaginal 
Table 1: PTB risk categories based on fFN concentrations.
Risk categories   fFN concentrations
1 – Low    < 10 ng/mL
2 – Lower middle   10–49 ng/mL
3 – Middle   50–199 ng/mL
4 – Upper middle  200–499 ng/mL
5 – High    ≥ 500 ng/mL
fFN, using a new bedside quantitative Rapid fFN 10Q 
System (Hologic), increases the diagnostic accuracy for 
PTB in pregnant women with signs and symptoms sugges-
tive of PTL.
The multicentre study was conducted in six Italian 
hospitals (Perugia, Florence, Turin, Bologna, Modena and 
Padua). The study-coordinating centre of Perugia vali-
dated the accuracy of data entry using supporting docu-
mentation from participating centres.
We prospectively enrolled 146 women with singleton 
pregnancy between 23+0 and the 33+0 weeks of gesta-
tion with self-reported signs and symptoms indicative of 
PTL. Gestational age was calculated on the last menstrual 
period and then confirmed by ultrasound.
The recruited patients reported signs and symptoms 
of PTL, as regular uterine contractions with or without 
pain, low abdominal cramping, low back pain and pelvic 
pressure. Besides, they presented clinically intact amni-
otic membranes as determined by speculum examination.
The Local Ethics Committee approved the study and 
informed written consent was obtained from each preg-
nant woman before the enrolment.
According to the protocols of each hospital, all 
recruited patients underwent a full clinical examination, 
including cervical length, cervical dilatation, amniotic 
membrane status and patient history investigation.
Pharmacological treatments such as atosiban, corti-
costeroids and magnesium sulfate were administered to 
all pregnant women enrolled in the study.
Materials and methods
Cervicovaginal sample for qfFN analysis was taken before cervical-
vaginal examination. According to the fFN test manufacturer’s 
instructions and the hospital protocols, we excluded patients with 
cervical dilation  > 3 cm, rupture of amniotic membranes, cervical 
cerclage, known or suspected placenta praevia, vaginal bleeding, 
twin or multiple pregnancy, sexual intercourse within 24 h and preg-
nant women with previous vaginal examination. Cervicovaginal 
fluids were sampled by using a Rapid fFN 10Q Specimen Collection 
Kit ( Hologic, Marlborough, MA, USA) composed of a sterile polyes-
ter swab and an extraction buffer vial. The swab was gently inserted 
into the vaginal cavity at the level of vaginal fornix for 10 s and then 
inserted into the collection vial containing the extraction buffer. 
We eliminated all the samples with blood-stained swabs because of 
interference with fFN  measurement.
After removing the swab from the vial, 200 μL of sam-
ple was immediately put in a Rapid fFN 10Q cassette (Hologic) 
and analysed, using the Rapid fFN 10Q analyser (Hologic), and 
results of the concentration of fFN were obtained in 10 min by 
TLilQ Analyzer software, version 2.0.0. The analyser detects a 
range of fFN concentrations from 0 to 500 ng/mL. Concentra-
tion of fFN higher than 500 ng/mL is shown as  > 500 ng/mL. The 
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internal controls were assessed using the Control Kit Rapid fFN 
(Hologic) which consists of a negative control for fFN concentration 
 < 50 ng/mL and a positive control for fFN concentration  > 50 ng/mL.
Results of fFN quantification, expressed in ng/mL, were 
grouped into five pre-specified incremental categories of PTB 
risks (Table  1,  < 10, 10–49, 50–199, 200–499 and  ≥ 500 ng/mL), as 
described by Abbott et al. [18].
Results of the qfFN test were blinded to the clinician’s manage-
ment decisions.
For each patient, results of fFN concentrations and clinical data 
including demographic, obstetric and gynaecological characteristics 
were entered in a database.
We followed all the pregnancies until delivery and the test-to-
spontaneous delivery interval was documented. Time to delivery was 
defined as the interval between the time and date when results of the 
qfFN test were performed and the time and date of spontaneous term 
or preterm delivery.
Statistical analysis
The diagnostic accuracy of fFN levels in predicting PTB 
was determined using receiver operating characteristic 
(ROC) curves, with cut-offs corresponding to the best com-
bination of high sensitivity and high specificity. A prelimi-
nary power analysis indicated that a sample of 10 from the 
positive group and 100 from the negative group achieve 
82% power to detect a difference of 0.27 between the 
area under the ROC curve (AUC) under the null hypoth-
esis of 0.50 and an AUC under the alternative hypothesis 
of 0.77 using a two-sided z-test at a significance level of 
0.05. Areas of ROC curves were compared with the Delong 
method [19].
The Shapiro-Wilk test was used to assess the normal 
distribution of variables and the Mann-Whitney test and 
the c2 test were used for comparisons of continuous and 
categorical variables, respectively. For an easier under-
standing, data are presented as mean±SD.
To calculate the odds ratios (ORs) linked to fFN levels, 
logistic regression (LR) models were fit for the prediction 
of PTB at delivery; the goodness of fit of LR models was 
checked using the Hosmer and Lemeshow test.
All statistical analyses were performed using IBM-
SPSS® version 22.0 (IBM Corp., Armonk, NY, USA, 2011). A 
two-sided P-value  < 0.05 was considered significant.
Results
A total of 126 women with singleton pregnancy who met 
the inclusion criteria were included in the study. We 
excluded 20 cases because we did not obtain pregnancy 
outcome.
Twelve women (9.5%) delivered before 34 weeks of 
gestation. Mean (±SD) gestational age at the time of qfFN 
testing for women who delivered before 34 weeks’ gesta-
tion was 27.42±4.31 and for those who delivered after 34 
weeks of gestation was 28.97±2.91 (P = 0.2). Mean (±SD) 
gestational age at delivery was 29.83±2.88 and 38.08±1.96 
weeks (P  ≤  0.001) before and after 34 weeks of gestation, 
respectively.
Of the women 80.16% had spontaneous onset of 
labour and 19.84% had pre-labour caesarean delivery.
Cervical length, at the time of qfFN testing was 
1.28±0.6  cm in women who delivered before 34 weeks 
of gestation and 2.47±0.99  cm (P  ≤  0.001) in those who 
delivered after 34 weeks. The diagnostic accuracy for 
delivery prediction of the cervical length determined by 
a ROC curve showed that the area under the ROC curve 
was 0.837 (95% CI, 0.760–0.898). The cervical length 
with a cut-off of 15  mm has a sensitivity of 66.67%, 
a  specificity  of 84.07%, a NPV of 96.94% and a PPV 
of 25%.
Concentrations of fFN were obtained using the Rapid 
fFN 10Q System. In the two groups of women who delivered 
before and after 34 weeks of gestation, fFN  concentrations 
were 321.67±215.24 ng/mL and 66.82±107.29  ng/mL, 
respectively (P  ≤  0.001). Based on fFN concentrations, in 
Table 2 we reported numbers and percentages of women 
with fFN results falling in each predefined fFN catego-
ries for PTB risks. We found the largest number of women 
Table 2: Distribution of spontaneous birth within fFN predefined PTB risk categories, before and after 34 weeks’ gestation.
  Patients n 
 
1 – Low 
( < 10 ng/mL)
 
 
2 – Lower middle 
(10–49 ng/mL)
 
 
3 – Middle 
(50–199 ng/mL)
 
 
4 – Upper middle 
(200–499 ng/mL)
 
 
5 – High 
( ≥ 500 ng/mL)
n (%) n (%) n (%) n (%) n (%)
Pregnant women with delivery 
 < 34 weeks’ gestation
  12  1 (8.3%)  1 (8.3%)  2 (16.7%)  3 (25.0%)  5 (41.7%)
Pregnant women with delivery 
 > 34 weeks’ gestation
  114  47 (41.2%)  31 (27.2%)  24 (21.1%)  11 (9.6%)  1 (0.9%)
Data are expressed as n (%).
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who delivered before 34 weeks of gestation (83.4%) was 
within categories 3–middle, 4–upper middle and 5–high 
of the fFN-predefined categories (fFN ≥ 50 ng/mL) with the 
highest percentage for the 5–high class of risk (41.7%). 
Furthermore, the largest number of women who delivered 
after 34 weeks of gestation (68.4%) was within categories 
1–low, and 2–lower middle of the fFN-predefined catego-
ries (fFN  ≤  50 ng/mL) (P < 0.001).
The diagnostic accuracy for delivery prediction of the 
qfFN testing was determined by a ROC curve (Figure  1). 
Results showed that the area under the ROC curve was 
0.845 (95% CI, 0.770–0.903), suggesting a good diagnostic 
accuracy of the Rapid fFN 10Q System.
The best cut-off among different fFN concentrations 
resulted in fFN concentration ranging from 200 to 499 
ng/mL corresponding to risk categories 4–upper middle. 
Based on this cut-off point the qfFN test showed a good 
sensitivity of 66.67%, high specificity and NPV of 89.47% 
and 96.2%, respectively, and a discrete PPV of 40%.
In Table 3, we reported the results of sensitivity, spec-
ificity, NPV and PPV of qfFN testing for each of the five 
fFN-predefined categories. Specifically, we observed that 
sensitivity decreases, from lower to higher categories with 
a value ranging from 100% (class 1) to 41.7% (class 5). The 
test showed a good specificity that increases with increas-
ing fFN concentrations, from low-fFN concentrations with 
values of 0% (class 1) to high-fFN concentrations with 
values of 89.5% and 99.1% (categories 4 and 5). NPV was 
higher than 90% among fFN-predefined categories, while 
PPV increases as function of fFN concentrations within 
Figure 1: Receiver operating characteristic curve analysis of 
diagnostic accuracy of qfFN testing for prediction of spontaneous 
preterm delivery at  < 34 weeks’ gestation.
predefined categories, from 9.5% for 1–low class to 83.3% 
for the 5–high class.
The diagnostic accuracy of the qfFN test and of the 
cervical length for the prediction of PTB did not reveal a 
significant difference as demonstrated by the compari-
son of the areas under the ROC curves (0.008, 95% CI, 
0–0.100, P = 0.839).
Odds ratio derived from logistic regression was 1.009 
(95% CI, 1.005–1.013), indicating that for each increased 
ng/mL of fFN concentration, the risk of PTB increase of 
1.009 times.
We found that 11 out of 126 women delivered within 
14 days from the testing and among these seven delivered 
before and four delivered after 34 weeks of gestation.
Based on fFN concentrations, in Table 4 we reported 
numbers and percentages of women who delivered within 
14 days from qfFN testing for each predefined fFN catego-
ries for PTB risks. We found the largest number of women 
who delivered within 14  days (81.9%) from fFN testing 
was within categories 3–middle (n. 3), 4–upper middle 
(n.  3)  and 5–high (n. 3) of fFN-predefined categories 
(fFN ≥ 50 ng/mL).
We also determined the diagnostic accuracy of the 
test for the delivery prediction within 14  days from the 
testing by a ROC curve analysis (Figure 2). The area under 
the ROC curve was 0.661 (95% CI, 0.330–0.902) showing a 
low diagnostic accuracy in the prediction of preterm deliv-
ery within 14 days.
In Table  5, we reported the results of sensitivity and 
specificity of qfFN test for the delivery prediction within 
14 days from testing for each fFN-predefined categories. In 
detail, we observed that sensitivity decreases, from lower 
to higher categories with a value ranging from 100% (class 
2–lower middle) to 42.86% (class 5–high) and specificity 
increases, from low fFN concentration with values of 0% 
(class 2–lower middle) to high fFN concentration with values 
of 50% and 100% (categories 4–upper middle and 5–high).
As qfFN test results were masked to clinicians, phar-
macological treatments were administered to all the 
pregnant women enrolled in the study. Pharmacological 
treatments administered to pregnant women include toco-
lytics, corticosteroids and tocolytics combined with corti-
costeroids, as reported in Table 6.
Discussion
The bedside qualitative fFN testing is a useful tool to iden-
tify pregnant women at risk for PTB. The presence of fFN 
in the cervicovaginal secretions in pregnancy has been 
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Table 3: Prediction of PTB at  < 34 weeks’ gestation.
Predictive variable   1 – Low 
( < 10 ng/mL)
  2 – Lower middle 
(10–49 ng/mL)
  3 – Middle 
(50–199 ng/mL)
  4 – Upper middle 
(200–499 ng/mL)
  5 – High 
( ≥ 500 ng/mL)
Sensitivity, %   100  91.7  83.3  66.7  41.7
95% CI   73.4–100  61.5–97.4  51.6–97.4  34.9–89.9  15.3–72.2
Specificity, %   0  41.2  68.4  89.5  99.1
95% CI   0–3.2  32.1–50.8  59.1–76.8  82.3–94.4  95.2–99.9
Negative predictive value, %  /  97.9  97.5  96.2  94.2
95% CI   /  93.9–102  94.1–100.9  92.6–99.9  90–98.4
Positive predictive value, %   9.5  14.1  21.7  40  83.3
95% CI   4.4–14.6  6.4–21.8  9.8–33.7  18.5–61.5  53.5–113.2
Data are expressed as %.
Table 4: Distribution of spontaneous birth within 14 days from fFN testing for each predefined PTB risk category.
 
 
Total (n) 
 
1 – Low 
( < 10 ng/mL)
 
 
2 – Lower middle 
(10–49 ng/mL)
 
 
3 – Middle 
(50–199 ng/mL)
 
 
4 – Upper middle 
(200–499 ng/mL)
 
 
5 – High 
( ≥ 500 ng/mL)
n (%) n (%) n (%) n (%) n (%)
Pregnant women who delivered 
within 14 days from fFN testing
  11  0  2 (18.2%)  3 (27.3%)  3 (27.3%)  3 (27.3%)
Data are expressed as n (%).
Figure 2: Receiver operating characteristic curve analysis of 
diagnostic accuracy of qfFN testing for prediction of spontaneous 
preterm delivery within 14 days of test.
definitively associated with an increased risk of PTB [7, 
14, 18]. Numerous studies, however, established that the 
bedside qualitative fFN testing has a limited diagnostic 
accuracy in the prediction of spontaneous delivery in 
symptomatic pregnant women because it is based only 
on one threshold (50 ng/mL) and for this reason is prone 
to false-positive and negative results around that cut-off 
point [15]. For this reason, the testing has a good NPV, but 
limited PPV  < 20% [7, 8, 11, 13].
Some studies, which measured cervicovaginal fFN 
concentration using an enzyme-linked immunosorbent 
assay (ELISA) analysis, showed that PTB risk is propor-
tional to cervicovaginal fFN concentration in symptomatic 
and asymptomatic pregnant women [14, 16, 17]. In a recent 
study, Abbott at al. [18] measured the level of fFN in cervico-
vaginal fluids of symptomatic woman at risk for PTB, evalu-
ating different fFN thresholds (from 10 to 500 ng/mL). They 
observed that increasing levels of fFN in  cervicovaginal 
fluids increase the risk for PTB and concluded that quanti-
tative information added its value in predicting PTB.
In the present multicentre study, we evaluated the 
new bedside qfFN testing (Rapid fFN 10Q System, Hologic) 
in the prediction of PTB before 34 weeks of gestation or 
within 14 days of testing in symptomatic pregnant women 
enrolled between 23+0 and 33+0 weeks of gestation. We 
measured the entire range of cervicovaginal fFN concen-
tration from 0 to 500 ng/mL and the results were then 
stratified in five predefined PTB risk categories, in order 
to assess the diagnostic accuracy of the test for each class. 
We examined the range from 23+0 to 34+0 weeks of gesta-
tion because in this period fFN in cervicovaginal fluid is 
usually absent and when the fluid is present it is a power-
ful predictor of PTB [3–5, 20].
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In the study, six Italian hospitals participated in 
recruiting 146 pregnant women between 23+0 and 33+0 
weeks’ gestation with signs and symptoms for preterm 
delivery. Each pregnant women underwent fFN testing by 
the Rapid fFN 10Q System in order to measure the fFN con-
centration within the cervicovaginal fluids. Based on the 
fFN concentration ranges, results were grouped in five-
predefined PTB risk categories as described in the Mate-
rial and methods section. Each predefined threshold for 
qfFN was used to establish the sensitivity, specificity, PPV 
and NPV for spontaneous delivery before 34 weeks of ges-
tation or within 14 days from the testing.
Among women who delivered at  < 34 weeks’ gesta-
tion (9.5% of the total enrolled pregnant women), 83.4% 
presented a high fFN concentration corresponding to the 
three higher-predefined categories for PTB risk, while 
16.6% of them had low fFN concentration corresponding 
to the lower predefined PTB risk categories.
The diagnostic accuracy of the qfFN testing for deliv-
ery prediction, calculated by a ROC curve analysis, was 
of 84.5%, indicating a high capacity to identify women at 
risk for PTB before 34 weeks’ gestation. Moreover, we cal-
culated the best threshold of the test in order to increase 
the PPV, and to enable the identification of true high-risk 
pregnant for PTB before 34 weeks’ gestation that was 
above 200 ng/mL. The specificity increased with each 
threshold reaching high values for the risk categories 4 
and 5 (89.5% and 99.1%, respectively). The sensitivity of 
the categories 4 and 5, unlike of the specificity, showed a 
reduction (66.7% and 41.7%, respectively), probably due 
to the pharmacological treatments administered to preg-
nant women. In fact, in this study, results of the test were 
blinded to the managing obstetrician and intervention 
(hospitalisation, tocolysis, corticosteroids) was performed 
based on the standard hospital practice.
The qfFN test improves the PPV for the prediction of 
PTB before 34 weeks, increasing with each fFN threshold 
(9.5, 14.1, 21.7, 40.0, 83.3%, respectively), while maintain-
ing a high NPV, confirming the results of Abbott et al. with 
respect to a single fFN threshold of 50 ng/mL (21.7%, our 
data not shown). The comparison of diagnostic accuracy 
of the qfFN test and of the cervical length for the delivery 
prediction showed a high capacity to identify women at 
risk for PTB for both.
Women (81.9%) who give birth within 14  days from 
testing presented a high concentration of fFN corre-
sponding to the three higher-predefined categories for 
PTB risk, while the 18.2% felt in the lower-middle class 
category; no cases were observed in the lowest class 
category. Diagnostic accuracy of the qfFN testing, cal-
culated by a ROC curve analysis, was 66.1%, indicating 
a low capacity to identify women at risk for PTB within 
14  days of testing. Sensitivity and specificity have the 
same trend observed for PTD delivery  < 34 weeks of gesta-
tion. Sensitivity showed a reduction from lower to higher 
categories, instead specificity increased with increasing 
fFN concentrations.
The results of our study are consistent with other 
studies [18] on quantification of cervicovaginal fFN 
in symptomatic pregnant women at risk for PTB. We 
Table 5: Prediction of PTB within 14 days from fFN testing.
Predictive 
variable
  1 – Low 
( < 10 ng/mL)
  2 – Lower middle 
(10–49 ng/mL)
  3 – Middle 
(50–199 ng/mL)
  4 – Upper middle 
(200–499 ng/mL)
  5 – High 
( ≥ 500 ng/mL)
Sensitivity, %   /  100  85.7  57.14  42.86
95% CI   /  58.9–100  42.2–97.6  18.8–89.6  10.4–81.2
Specificity, %   /  0  25  50  100
95% CI   /  0.0–59.8  4.1–79.7  8.3–91.7  40.2–100
Data are expressed as %.
Table 6: Pharmacological treatments administered to all pregnant women.
  Patients, n  Pregnant women 
given tocolytics, 
n (%)
  Pregnant women 
given corticosteroids, 
n (%)
  Pregnant women 
given tocolytics + 
corticosteroids, n (%)
  Pregnant women 
not given drugs, 
n (%)
Pregnant women with delivery  
 > 34 weeks’ gestation
  114  10 (8.8%)  19 (16.7%)  31 (27.2%)  54 (47.4%)
Pregnant women with delivery  
 < 34 weeks’ gestation
  12  1 (8.3%)  3 (25%)  5 (41.7%)  3 (25%)
Data are expressed as n (%).
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observed that the relationship between fFN concentra-
tion in cervicovaginal fluid and PTB risk is linear, with 
increased concentrations inferring a greater risk of 
delivery.
We observed that minimal increase in fFN (1–49 ng/
mL) is associated with a low increase in risk of PTB; mod-
erated increase in fFN (50–199 ng/mL) is associated with a 
moderate increase in PTB risk; finally a significant increase 
in fFN (200–499 ng/mL and  ≥ 500 ng/mL) is associated 
with a significant increase in PTB risk. We also observed 
that a high cut-off, above  > 200 ng/mL, significantly 
increases the PPV (with minimal effect on the NPV) for 
delivery before 34 weeks of gestation. On the other hand, 
we obtained a poor diagnostic accuracy of the fFN within 
14 days of testing probably due to the therapy administra-
tion which may have affected the outcome of pregnancy. 
In this study, results of the fFN test were blinded to the 
clinician’s management decisions and intervention (hos-
pitalisation, tocolysis, corticosteroids) was performed 
based on the standard hospital practice. Randomised 
clinical trials have found that tocolytic therapy results in 
a prolongation of pregnancy of 48 h to 7 days providing 
time for beneficial measures such as transfer to a level III 
perinatal centre and administration of corticosteroids for 
the enhancement of lung maturation [21].
In conclusion, the use of the bedside qfFN testing 
before 34 weeks’ gestation in pregnant women with signs 
and symptoms of PTB allows: (1) the clinicians to adapt 
their decisions based on the different fFN testing thresh-
olds; (2) the identification of true low-risk pregnancy 
who will be reassured that the risk of very PTB is very low 
because the test has a high NPV; (3) the identification of 
true high-risk pregnancy for PTB who needed antenatal 
treatment because the test has a good PPV.
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